1 / 2

Novartis defends its runner up position on #2 with total RX sales of USD 54 billion in 2011

PharmExec 50 – PharmExec magazine For the second consecutive year, Novartis is the second biggest company by Rx Sales in 2011. Novartis defends its runner up position on #2 with total RX sales of USD 54 billion in 2011

midori
Télécharger la présentation

Novartis defends its runner up position on #2 with total RX sales of USD 54 billion in 2011

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PharmExec 50 – PharmExec magazineFor the second consecutive year, Novartis is the second biggest company by Rx Sales in 2011 • Novartis defends its runner up position on #2 with total RX sales of USD 54 billion in 2011 • Merck climbs up one position to #3 but, with Rx sales of USD 41.3 billion, remains significantly behind Novartis PharmExec 50 1 | Novartis Ranking Results 2012| Business Use Only

  2. PharmExec 50 – PharmExec magazineNovartis is again one of the top companies in the US • Novartis is 4th (based on sales) and 3rd (in number of prescriptions) in the US ranking • With an increase of almost 7%, Novartis belongs to the biggest gainers on the US sales list Top 20 companies by US sales in 2011 Top 25 companies by US prescriptions 2011 2 | Novartis Ranking Results 2012 | Business Use Only

More Related